Web13 sep. 2024 · The current mainstay of hepatitis B treatment is antiviral therapy with pegylated interferons or oral nucleoside/nucleotide analogues, which are also used in HIV. These drugs can suppress viral replication but patients must be treated chronically, and adherence can be low – hence the need for a functional cure. WebOn August 28, 2024, Ionis Pharmaceuticals, which focuses on the development of RNA-targeted antisense oligonucleotide drugs, announced positive results for IONIS-HBVRx and IONIS-HBV-LRx, which are in phase II clinical trials for the treatment of chronic hepatitis B. GlaxoSmithKline will develop and promote these two research therapies.

GSK hepatitis B hope bepirovirsen heads for phase 3 test

Web5 aug. 2024 · Oligonucleotide therapeutics are an emerging class of drugs that have tremendous potential for treating a wide range of diseases. 1 There are now nine marketed oligonucleotide products, 2 and nusinersen (Biogen/Ionis), which is used to treat spinal muscular atrophy, generated more than $2 billion in sales in 2024. Web8 nov. 2024 · Bepirovirsen is one of the ASO HBV programme assets in-licensed by GSK from Ionis Pharmaceuticals in August 2024. About GSK at AASLD In addition to the full study results for the B-Clear trial, GSK will share updates on its specialty and vaccines pipeline at the AASLD meeting in Washington DC, including: imap 1 and 1

Ionis announces positive data from GSK

Web16 feb. 2024 · IONIS- HBV Rx: HBV surface Ag, Liver: 150–300 mg once weekly, SC: HBV, chronic atypical (Ionis/GSK) Phase 2 findings included dose dependent reductions of … Web8 nov. 2024 · CARLSBAD, Calif., Nov. 8, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that GSK presented positive end of study data from the Phase 2b B-Clear study of... WebASO treatment effectively reduced HBsAg in combination with entecavir, while the nucleoside analogue alone did not. ASO treatment has pan-genotypic antiviral activity in … imap4 fetch